Systemic amyloidoses are disorders caused by amyloid deposits in various tissues, leading to progressive organ failure and death. For any amyloidosis type, heart involvement is fundamental for prognostication. In light chain (AL) amyloidosis, the heart is involved in 70% to 80% of patients.1-4  For age-related transthyretin amyloidosis (wild-type ATTR [ATTRwt]), virtually all patients have cardiac involvement, whereas the majority of hereditary ATTR (also mutant ATTR [ATTRmt]) have cardiac involvement.

Soluble cardiac biomarkers are invaluable for decision making in AL amyloidosis, and data are emerging about their importance in ATTR amyloidosis.5,7  With a changing landscape of cardiac biomarker assays, risk models may appear inaccessible. However, there are opportunities for harmonization. We briefly discuss the evolution of cardiac biomarker use in systemic amyloidoses and provide a conversion tool between cardiac troponin T (cTnT) and high-sensitivity cardiac...

You do not currently have access to this content.